Bio‑Techne Corporation announced the launch of its Simple Plex Ultra‑Sensitive Assays on the Ella automated benchtop platform, a move that expands the company’s research‑grade assay portfolio into the high‑stakes field of neurodegenerative disease biomarkers. The new assays deliver femtogram‑level detection of neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), phosphorylated tau 217 (pTau 217), and amyloid‑β (aa1‑42), and complete a run in under three hours thanks to the platform’s fully automated microfluidic workflow.
The launch is a strategic operational milestone that positions Bio‑Techne to capture a growing market for early‑diagnostic tools in Alzheimer’s, ALS, Parkinson’s and other neurodegenerative disorders. By enabling researchers to detect biomarkers at femtogram concentrations, the assays allow for the identification of subtle, early disease changes that conventional immunoassays often miss. This capability is expected to accelerate the discovery of therapeutic targets and improve the design of clinical trials, aligning with the company’s broader focus on high‑impact research tools.
Will Geist, President of Bio‑Techne’s Protein Sciences Segment, emphasized the significance of the new assays: “The introduction of Simple Plex Ultra‑Sensitive assays on Ella significantly advances the analytical capabilities available for neurodegenerative disease research. By combining femtogram‑level detection with a fully automated microfluidic platform, Ella enables precise quantification of low‑abundance biomarkers that are often undetectable with conventional immunoassay methods.” He added that the enhanced sensitivity and reproducibility support earlier characterization of disease‑related changes and strengthen the reliability of high‑throughput studies aimed at defining disease trajectories and identifying novel therapeutic targets.
The launch comes as Bio‑Techne reports Q1 FY2026 net sales of $286.6 million, a slight decline from the prior year, but with a gross margin that improved to 65.6% from 63.2%. The margin expansion reflects the company’s focus on high‑margin research‑grade products and operational efficiencies, even as overall sales face modest headwinds. The new Ella assays are designated for “Research Use Only” and are not cleared for clinical diagnostic use, but they reinforce Bio‑Techne’s position as a leading provider of advanced analytical tools for the life‑science community.
The addition of ultra‑sensitive neurodegenerative biomarkers to the Ella platform strengthens Bio‑Techne’s competitive advantage, as the platform already enjoys a strong publication record with over 200 neurology‑focused citations and more than 1,000 instruments in operation worldwide. The launch is expected to drive further adoption among academic and industry researchers seeking rapid, reproducible, and highly sensitive assays for early disease detection and therapeutic development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.